Unity Looks Ahead To Pivotal Study With Positive DME Data For UBX1325

UNITY Biotechnology, Inc. is well-positioned to move UBX1325 into pivotal development for diabetic macular edema (DME) in patients who had reached a therapeutic plateau with standard-of-care anti-VEGF treatment, following results of a Phase II study that showed a clear benefit to patients from the therapy.

Unity announced results from the BEHOLD study on 1 November, comparing UBX1325 against sham treatment in an analysis of 59 patients. The company said that, based on the findings, it...